GLUE - Monte Rosa Therapeutics Inc

https://www.monterosatx.com

Buy Momentum: Bearish

Recent News

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Monte Rosa Therapeutics ( NASDAQ:GLUE )

Benzinga • 19 minutes ago • score: 0.10

Monte Rosa's volume jumps to 11.67 million vs. an average of 408K after announcing collaboration with Novartis. Monte Rosa gets $120 million upfront and could earn up to $5.7 billion in milestones and royalties. Up Next: Wall Street trader's 34-0 strategy goes public this week. See it first →

Neutral

Monte Rosa Therapeutics ( GLUE ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.07

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of +51.61% and +118.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.

52W High

$12.40

52W Low

$3.50

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.42

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

12.67

Forward P/E (<15 better)

10.86

EV/EBITDA (<8 favorable)

2.39

EV/Revenue (<3 favorable)

0.31

P/S (TTM) (<3 favorable)

1.71

P/B (<3 favorable)

1.14

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.73%

Institutions (25–75% balanced)

100.42%

Shares Outstanding

61,759,000

Float

30,303,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

177,986,000

Gross Profit (TTM)

56,550,000

EPS (TTM)

0.39

Profit Margin (>10% good)

0.14%

Operating Margin (TTM) (higher better)

-0.67%

ROE (TTM) (>15% strong)

0.10%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

3.94

Momentum

Bearish momentum

Value

0.0253

0.0295

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025